David Liu (Broad Institute)
July 28, 2022 11:00 AM EDTUpdated 03:13 PM
R&D
Discovery

David Li­u's lab de­vel­ops next-gen base ed­i­tors, small enough to fit in­to sin­gle AAV

Aayushi Pratap

News Reporter

Re­searchers use ade­no-as­so­ci­at­ed virus­es (AAVs) as ve­hi­cles to de­liv­er CRISPR/Cas sys­tems, cor­rect gene copies and DNA and RNA se­quences in­to hu­man cells as treat­ment modal­i­ties …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times